Overview
No overview information available.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Research Report
NKT-2152: An Investigational HIF2α Inhibitor for Advanced Solid Tumors
1. Executive Summary of NKT-2152
NKT-2152 is an orally bioavailable, small molecule investigational therapeutic agent designed to inhibit Hypoxia-Inducible Factor 2α (HIF2α), a transcription factor implicated as a key oncogenic driver in various malignancies. Developed by NiKang Therapeutics® Inc., NKT-2152 is currently undergoing clinical evaluation for the treatment of advanced solid tumors, with a pronounced focus on clear cell Renal Cell Carcinoma (ccRCC) and Hepatocellular Carcinoma (HCC).[1]
The development program for NKT-2152 has yielded significant preclinical anti-tumor activity and has progressed to demonstrate promising efficacy signals in early-phase human clinical trials. These positive signals are particularly evident in heavily pretreated ccRCC patient populations, an area with substantial unmet medical need. A distinguishing characteristic of NKT-2152 is its unique pharmacokinetic (PK) profile, notably featuring a long terminal half-life, which is believed to support sustained target engagement and may offer dosing advantages.[1] The clinical development of NKT-2152 is robust, encompassing investigations of the agent both as a monotherapy and in various combination regimens. This comprehensive program is supported by strategic collaborations with several major pharmaceutical companies, facilitating broader and more rapid evaluation.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2023/09/21 | Phase 1 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | ||
2023/07/07 | Phase 2 | Active, not recruiting | |||
2020/08/24 | Phase 1 | Recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.